TFEB and amyotrophic lateral sclerosis: The nodal function of TFEB in ALP promoted the development of TFEB-based gene therapy predominantly by its overexpression to treat lysosomal storage disorders, which was successfully tested in cell and mouse models of Pompe’s disease [22,23], Gaucher’s disease [24], and amyotrophic lateral sclerosis [25].